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Abstract
The turnover of extracellular matrix liberates various cryptic molecules with novel biological activity. Among these are the
collagen-derived anti-angiogenic fragments, some of which are suggested to affect carcinoma cells also directly. Arresten is
an endogenous angiogenesis inhibitor that is derived from the non-collagenous domain of the basement membrane
collagen IV a1 chain. As the mere prevention of tumor angiogenesis leads to hypoxia that can result in selection of more
aggressive cell types and reduces the efficacy of chemotherapy, we aimed here to elucidate how arresten influences the
aggressive human carcinoma cells. Arresten efficiently inhibited migration and invasion of HSC-3 tongue carcinoma cells in
culture and in an organotypic model. Subcutaneous Arr-HSC xenografts grew markedly more slowly in nude mice and
showed reduced tumor cell proliferation, vessel density and local invasiveness. In the organotypic assay, HSC-3 cells
overproducing arresten (Arr-HSC) showed induction of cell death. In monolayer culture the Arr-HSC cells grew in
aggregated cobblestone-like clusters and, relative to the control cells, showed increased expression and localization of
epithelial marker E-cadherin in cell-cell contacts. Application of electric cell-substrate impedance sensing (ECIS) further
supported our observations on altered morphology and motility of the Arr-HSC cells. Administration of a function-blocking
a1 integrin antibody abolished the impedance difference between the Arr-HSC and control cells suggesting that the effect
of arresten on promotion of HSC-3 cell-cell contacts and cell spreading is at least partly mediated by a1b1 integrin.
Collectively, our data suggest novel roles for arresten in the regulation of oral squamous carcinoma cell proliferation,
survival, motility and invasion through the modulation of cell differentiation state and integrin signaling.
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Introduction
Tumor growth does not just depend on carcinoma cells, as
interactions between cancer cells, extracellular matrix (ECM) and
various cell types in the tumor stoma have a major impact on the
disease outcome. The remodeling of tumor stroma during
tumorigenesis and the cleavage of basement membrane compo-
nents results in molecules with novel biological activities [1,2].
Particularly, collagens IV and XVIII contain cryptic fragments,
named arresten, canstatin, hexastatin, tetrastatin, tumstatin and
endostatin, which inhibit angiogenesis and tumor growth via
integrin binding [3–15]. Arresten is a 26-kDa fragment derived
from the non-collagenous NC1 domain of the basement mem-
brane collagen IV a1 chain [a1(IV)NC1] that efficiently inhibits
the proliferation, migration and tube formation of different types
of endothelial cells [3,16–18]. In vivo, arresten inhibits Matrigel
neovascularization [18] and the growth of subcutaneous tumors in
mice [3,16,18]. It has recently been shown that it also increases
apoptosis of endothelial cells by regulating intracellular signaling
events. The pro-apoptotic effect of arresten is mediated by
reducing the expression of the anti-apoptotic signaling molecules
Bcl-2 and Bcl-xL and activating caspase-3/poly (ADP-ribose)
polymerase via FAK/p38-MAPK signaling [2,19]. The pro-
duction of arresten has recently been linked to the p53 tumor
suppressor pathway. p53 was shown to induce an anti-angiogenic
program whereby expression of a1(IV) chain is upregulated,
stabilized by prolyl-4-hydroxylase and efficiently processed by
MMPs to an arresten-containing peptide. This p53-dependent
ECM remodeling was suggested to destabilize the vascular
collagen IV network and thereby prevent endothelial cell adhesion
and migration leading to reduced angiogenesis and tumor growth
in vivo and in vitro. [20].
Tumor cell invasion resulting in metastasis is the main cause of
cancer mortality rather than primary tumor growth, and the
tumor microenvironment plays a critically important role in this
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invasion process [21]. In order to metastasize, the tumor cells
undergo epithelial-to-mesenchymal transition (EMT)-like events
whereby they lose their polarity, and cell-cell and cell-matrix
contacts. The acquired mesenchymal, de-differentiated and motile
characteristics facilitate cell movement and invasion to novel
metastatic locations. The molecular hallmarks of EMT are
downregulation of the cell-cell adhesion molecule E-cadherin
and upregulation of many mesenchymal markers [22–24]. ECM
composition and remodeling affect the differentiation state and
behavior of tumor cells [25,26]. For example, increased expression
and crosslinking of collagen I and IV are suggested to promote
EMT, tumor progression and metastasis [27–30]. EMT is
a reversible process; during mesenchymal-to-epithelial transition
(MET) the cells become again non-motile [22,31].
The complex interactions between cells and ECM molecules are
largely regulated through integrins and other cell surface receptors
[32,33]. Particularly collagen IV has been shown to be the binding
substrate of integrins in many cell types, including tumor cells, and
its binding to different integrin subtypes may vary depending on its
remodeling state [34]. Integrin binding triggers intracellular
signaling events that contribute to cancer progression. The
pathways leading to EMT via regulation of cadherins requires
co-operative signals from integrins [32,33].
As arresten has effects on other cell types in the tumor
microenvironment besides endothelial cells [18], we focused here
on its impact on highly metastatic human tongue squamous cell
carcinoma HSC-3 cell line. By using in vitro cell culture assays,
organotypic invasion and in vivo mouse xenograft models, we show
that overexpression of arresten promotes epithelial morphology,
and efficiently inhibits proliferation, migration and invasion of
carcinoma cells, and induces their apoptosis, leading to suppres-
sion of tumor growth and progression.
Results
Arresten Inhibits Carcinoma Cell Migration in vitro
After stable transfections, the expression of recombinant
arresten was verified in three separate clones of HSC-3 tongue
squamous cell carcinoma cells, and also in two MDA-MB-435
breast carcinoma cell clones. By comparison to the parental cells,
these stable cell lines showed a substantial increase in arresten
expression at mRNA level as ascertained by qPCR (Table S1).
More importantly, a ,29 kDa Flag-tagged arresten was detected
by Western blotting in the conditioned medium (CM) collected
from Arr-HSC and Arr-MDA cells (Figure S1A–B). The following
experiments were performed using Ctrl-HSC(1) and Arr-HSC(1)
(Figure S1) clones unless otherwise stated.
To study the effects of arresten on carcinoma cells, we first
performed Transwell migration experiments and found that the
Arr-HSC cells migrated significantly less than the control cells
(p,0.001) (Figure 1A). The addition of exogenous human
recombinant arresten had a similar inhibitory and dose-dependent
effect on Ctrl-HSC cell migration in Transwell assay (Figure 1B).
Furthermore, the Arr-HSC clones showed a clear non-migratory
phenotype in the scratch wound healing assay, whereas the control
cells almost closed the wound within 48 h (Figure 1C–D, Figure
S2A and S2C). Also the Arr-MDA breast carcinoma cells were
statistically less motile than the Ctrl-MDA cells in the wound
healing assay (Figure S2B and S2D). HSC-3 cell proliferation,
measured by BrdU incorporation into the DNA-synthesizing cells,
was not affected by the overexpression of arresten within 24 h
(Figure S3A), but a reduced number of viable arresten cells was
observed in the MTT assay in a longer experimental set-up (68 h)
in monolayer culture (p = 0.001) (Figure S3B).
To confirm that the observed significant change in the Arr-HSC
cell motility was not due to an artifact of overexpression, but rather
to the secretion of arresten into the culture medium we collected
CM from the Arr-HSC cells, transferred it to Ctrl-HSC cells and
measured the effect on cell migration by Transwell assay. The
migration of Ctrl-HSC cells decreased approximately 40% in the
presence of conditioned Arr-HSC medium (p,0.001) (Figure
S4A). To verify that the secreted arresten did not become
degraded during the co-culture period, we collected CM for
Western blot analysis at various time points of culture. This
analysis showed that no protein degradation occurred during the
72 h culture period (Figure S4B).
Arresten Reduces Tumor Vasculature and Suppresses
Growth and Invasion of HSC-3 Xenografts
Ctrl-HSC or Arr-HSC carcinoma cells were injected sub-
cutaneously into nude mice and tumor growth was monitored for
16 days. The Arr-HSC tumors grew significantly more slowly than
the control tumors (Figure 2A). In addition, some differences in
local tumor invasion were noted between Arr-HSC and Ctrl-HSC
xenografts upon histopathological examination (Figure 2B–C).
Most (,80%) of the arresten tumors had not invaded into the
surrounding tissue, whereas half of the control tumors showed at
least minor score of invasiveness (Figure 2B). Our observation of
the less invasive phenotype of Arr-HSC xenografts was supported
by an in vitro experiment, where the Arr-HSC cells invaded less
through Matrigel than the Ctrl-HSC cells (Figure S5). Immunos-
taining of HSC-3 xenografts for Ki-67 revealed almost 70%
reduction in the amount of proliferative cells in arresten tumors
(p,0.001) (Figure 2D–E), at least partly explaining the smaller size
of these tumors. Since arresten is a potent inhibitor of
angiogenesis, the amount of tumor blood vessels was determined.
The blood vessel density reduced almost 50% (p,0.001) in the
arresten xenografts relative to the control tumors (Figure 2F–G).
Histological analysis of HSC-3 xenografts revealed that besides
being smaller the Arr-HSC tumors also more often contained
central keratinized areas and keratin pearls, indicating higher
degree of differentiation, and the proportion of the surrounding
poorly differentiated tumor cell layer was smaller than in the
control tumors (Figure S6A–D). E-cadherin staining showed either
diffuse cytoplasmic signals in the poorly differentiated tumor areas,
or membranous staining within the keratinized areas in all
xenografts (Figure S6E–H).
Arresten Inhibits HSC-3 Carcinoma Cell Invasion in the 3D
Organotypic Model
To further explore the invasive properties of the Arr-HSC cells
and to gain insight into the mechanisms of action of arresten, we
performed three-dimensional (3D) organotypic assays in which
HSC-3 carcinoma cells were allowed to invade into a collagen
matrix supplemented with human gingival fibroblasts. After a 2-
weeks culture period, the organotypic sections were immunos-
tained with E-cadherin and pancytokeratin AE1/AE3 antibodies,
and the maximal invasion depth and area, and the thickness of the
top cell layer were determined. As expected, the Ctrl-HSC cells
invaded deep into the collagen matrix and E-cadherin staining
clearly decreased in the matrix-invaded cells indicating loosening
of the cell-cell contacts during the invasion (Figure 3A–B).
Arresten overexpression almost completely blocked HSC-3 cell
invasion, the maximal invasion depth and the area of invading
cells being significantly smaller than those of the control cells.
Relative to the Ctrl-HSC cells, the Arr-HSC cells also formed
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a very thin top cell layer, with prominent membranous E-cadherin
staining (Figure 3A–D).
Arresten Overexpression Promotes an Epithelial
Morphology and E-cadherin in Cell-cell Contacts
Besides the non-migratory and less invasive phenotype of Arr-
HSC cells observed in the previous assays, we noticed a prominent
change in their cell morphology. Compared to the control HSC-3
cells, the Arr-HSC clones displayed a flatter, less spindle-shaped
phenotype and they grew in aggregated cobblestone-like clusters
(Figure 4A). Similar morphological changes were observed in
MDA-MB-435 breast carcinoma cells in the presence of excess
arresten (Figure S2E), These findings led us to hypothesize that
arresten may affect the epithelial plasticity of the HSC-3 cells, and
induce a switch from the mesenchymal carcinoma cell phenotype
to a one resembling normal epithelial cells. The carcinoma cells
undergo EMT-like events during cancer progression, and a re-
versed process MET is suggested to occur, endowing a less motile
phenotype [22,31]. Accordingly, we further investigated whether
arresten overexpression could restore the epithelial characteristics
of the tumor cells. The Arr-HSC cells growing in tightly packed
clusters expressed more epithelial marker E-cadherin on their cell
surfaces than the Ctrl-HSC cells (Figure 4B), which is likely to
contribute to their epithelial-like morphology and reduced
motility. Besides the recruitment of E-cadherin to the Arr-HSC
cell membrane, its expression in these cells was increased when
compared to the Ctrl-HSC cells (Table S1, Figure 4C–E). The
amount of E-cadherin mRNA in the Arr-HSC cells was 1.9-fold
60.06 (p,0.001) (Table S1, Figure 4E), and that of protein 1.6-
fold 60.12 (p = 0.019), both significantly higher than in control
cells (Figure 4C–D). Strong immunofluorescence signals for the
mesenchymal marker vimentin were observed in some individual
Ctrl-HSC and Arr-HSC cells, but evident differences in these
signals could not be detected between the cell lines (Figure S7).
Arresten Affects Cell Proliferation and Apoptosis of HSC-3
Cells in vitro
We next wished to determine the reason underlying the thin top
cell layer formed by the Arr-HSC cells in the organotypic model,
and set out to study tumor cell proliferation and apoptosis. The
number of proliferating Ki-67-positive tumor cells was smaller, but
not statistically significant, in the Arr-HSC than in the Ctrl-HSC
3D cultures (Figure 5A–B), which is in agreement with our
observation on reduced tumor cell proliferation in Arr-HSC
xenografts (Figure 2D–E). The TUNEL assay showed that the
Arr-HSC cells underwent apoptosis more often than the control
cells in the 3D model (Figure 5C–D). Since the TUNEL assay also
detects other types of cell death in addition to apoptosis, we
wanted to confirm our finding by caspase-3 staining. We observed
a similar and significant (p = 0.030) trend on increased apoptosis in
Arr-HSC cells (Figure 5E–F) although the increase was milder
than the one in the TUNEL assay. In HSC-3 xenografts, however,
only few TUNEL-positive cells were detected mainly in the
keratinized central tumor areas (Figure S8). We have previously
shown that recombinant arresten affects mitochondrial apoptosis-
related Bcl-family signaling molecules in microvascular endothelial
cells [18]. In the current experiment the pro-apoptotic Bax protein
showed 1.9-fold 60.23 increase in the Arr-HSC cells relative to
the Ctrl-HSC cells (p = 0.046), whereas the anti-apoptotic Bcl-xL
protein level concomitantly showed a decreased, although not
statistically significant, trend to 0.8-fold 60.049 of the controls
Figure 1. Arresten inhibits migration of HSC-3 cells. A. 30 000 Ctrl-HSC and Arr-HSC cells were allowed to migrate through Transwell inserts
and the number of migrated cells was counted under a microscope at 506magnification. Mann-Whitney U-test, ***p,0.001, (n = total number of
fields analyzed, 2–4 fields per Transwell insert). B. 30 000 HSC-3 cells were allowed to migrate through Transwell inserts in the presence of human
recombinant purified arresten (5 and 20 mg/ml) and the number of migrated cells was counted as described above. Mann-Whitney U-test, **p,0.01,
(n = total number of fields analyzed, 3–5 fields per Transwell insert). C. Scratch wound healing assay with Ctr-HSC and Arr-HSC clones in which the
closure of the wound was measured at 0, 16 and 48 h. Scale bar 50 mm. E. Quantification of scratch wound healing in the Ctrl-HSC and Arr-HSC
clones. Mann-Whitney U-test, ***p,0.001, (n = 70 fields at 0, 16 and 48 h per clone).
doi:10.1371/journal.pone.0051044.g001
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(p = 0.12), thus shifting the balance towards a situation favoring
apoptosis (Figure 5G–H).
Electric Cell-substrate Impedance Sensing Reveals
Alterations in Arr-HSC Cell Spreading and Cell-cell
Contacts
To pursue the mechanisms underlying the altered behavior and
morphology of Arr-HSC cells we performed measurements using
electric cell-substrate impedance sensing (ECIS), a method that
provides quantitative data on cell attachment, spreading and the
strength of cell-cell contacts by monitoring changes in the system
impedance [35]. The Arr-HSC cells showed markedly higher
impedance at a low frequency than the control cells (Figure 6A).
Also the HSC-3 cells treated with ArrCM showed higher
impedance than those treated with CtrlCM (Figure S9A). The
change in the impedance can be related either to cell inherent
dielectric properties, formation of cell-cell junctions or cell-
substrate interactions, and a mathematical ECISTM Model can
be applied to distinguish these parameters from each other [36].
Thus, a cell membrane capacitance (Cm) reflects the structure and
folding of cell membrane, a barrier resistance (Rb) refers to
establishment of cell-to-cell junctions, and a cell-substrate in-
teraction parameter a is linearly related to the cell surface area
and, inversely, to the distance between cell and substrate [36–38].
This modeling supported our observations on altered cell
morphology and E-cadherin of the Arr-HSC cells. First, signifi-
cantly increased Rb of the Arr-HSC cells relative to the Ctrl-HSC
implied tightening of intercellular junctions (Figure S9C). As we
Figure 2. Effects of arresten on HSC-3 xenografts. A. One million Ctrl-HSC and Arr-HSC cells were injected subcutaneously into the flanks of
nude mice and tumor growth was monitored over 16 days. Students t-test, *p,0.05, (n = 10 mice per group). B. Local invasiveness of the tumors. C.
Representative hematoxylin-eosin stainings of HSC-3 xenografts. Scale bar 100 mm. D–E. HSC-3 xenografts were stained for the proliferation marker
Ki-67 (brown) and the cell proliferation was defined as a percentage of Ki-67-positive cells among the total number of carcinoma cells per microscopic
field (4006magnification; n =number of fields analyzed, 3–5 fields per xenograft). Scale bar 50 mm. F–G. The tumor blood vessels were stained with
a CD31 antibody and counted under a microscope (2006magnification; n = number of fields analyzed, 3–5 fields per xenograft). Mann-Whitney U-
test, ***p,0.001. Scale bar 100 mm.
doi:10.1371/journal.pone.0051044.g002
Arresten Inhibits Carcinoma Cell Invasion
PLOS ONE | www.plosone.org 4 December 2012 | Volume 7 | Issue 12 | e51044
did not observe apparent changes in the cell size between the HSC
clones by phase contrast microscopy or immunofluorescent
stainings (Figure 4A–B), the higher a value of Arr-HSC cells can
be attributed to a better cell adhesion to the substratum (Figure
S9D). Lastly, altered Cm of Arr-HSC cells further points to
differences in the cell morphology and cell membrane properties
(Figure S9E).
The signaling through b1 integrin is known to affect E-cadherin
dynamics, and cell motility and EMT are abrogated by integrin
knockdown [38–41]. a1b1 integrin was identified as a functional
receptor for arresten on endothelial cells [3,16,18], but to date the
arresten receptors on carcinoma cells have not been identified.
HSC-3 cells express several integrin receptors, including a1b1 and
a2b1 (unpublished FACS data). We thus performed ECIS
experiments with Arr-HSC cells in the presence of function-
blocking antibodies for collagen binding integrins a1b1 and a2b1.
Administration of integrin a1 antibody decreased the impedance
of the Arr-HSC cells while that of the control cells remained
unaltered (Figure 6B–C). Incubation of Arr-HSC cells with the
integrin a2 blocking antibody almost completely inhibited the cell
spreading, but also control cells showed reduced impedance in the
presence of this antibody. Control IgG did not have any effect on
the behavior of the cells (Figure S9B). These data suggest that
integrin a1b1 is able to bind arresten also on oral squamous
carcinoma cells, resulting in changes in the cell morphology and
motility.
Discussion
Tumor growth and metastasis depends on local neovasculariza-
tion induced by hypoxic conditions and regulated by the tumor
microenvironment, including the components of the ECM.
Figure 3. Arresten efficiently inhibits HSC-3 carcinoma cell invasion in an organotypic model. A. Ctrl-HSC and Arr-HSC cells (76105) were
cultured on top of a collagen gel embedded with human gingival fibroblasts (76105). The organotypic sections were stained with E-cadherin
antibody (brown). Scale bar 20 mm. Tumor cell invasion and growth were quantified by measuring the maximal invasion depth (B), invasion area (C)
and area of the top cell layer of pancytokeratin stained sections (D). Mann-Whitney U-test, ***p,0.001, *p,0.05, (n = total number of fields analyzed,
4–5 fields per organotypic section).
doi:10.1371/journal.pone.0051044.g003
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Arresten is one of the five thus far identified basement membrane
collagen IV-chain-derived fragments that can inhibit angiogenesis
and thereby reduce tumor growth via integrin binding [3–13,15].
Arresten binds to integrin a1b1 on endothelial cells to regulate the
actin cytoskeleton and migration [3,16,18]. Besides the expected
anti-angiogenic effect of arresten in mouse xenograft tumors, we
demonstrate here that it directly affects oral carcinoma cells both
in vivo and in vitro. This is the first time that the direct effects of
arresten on other cell types than endothelial cells have been
studied in more detail.
Here the overexpression of arresten strongly inhibited oral
squamous cell carcinoma cell invasion in Matrigel Transwell assay
and in organotypic 3D model. Arresten also clearly reduced the
migration of these cells, as well as MDA-MB-435 carcinoma cells,
in monolayer culture. In an in vivo tumor burden model arresten
overexpression led to a smaller tumor size, impaired angiogenesis,
and changes in tumor tissue architecture. Since human sub-
cutaneous xenograft tumors rarely metastasize in nude mice [42],
we assessed the amount of local invasion and found that Arr-HSC
tumors invaded less into the surrounding tissue than the control
tumors.
In order to explore the reasons underlying the significantly
smaller size of subcutaneous Arr-HSC xenografts and thin top cell
layer formed by the Arr-HSC cells in the organotypic model, we
analysed tumor cell proliferation and apoptosis in these samples.
Compared to Ctrl-HSC cells, a reduced number of proliferating
Ki-67-positive Arr-HSC cells were detected in both models.
Furthermore, the MTT assay showed a smaller number of viable
HSC-3 cells in response to arresten in long-term monolayer
culture, although previously we did not observe increased
apoptosis-related caspase-3 activity of HSC-3 cells by short-term
exposure to recombinant arresten [18]. Arresten has been shown
to exert a pro-apoptotic effect on various types of endothelial cells
in vitro, and both on endothelial and tumor cells in an in vivo mouse
tumor burden model [16,18]. Our current findings show
significantly increased number of TUNEL-positive cells and also
a slightly elevated number of caspase-3 positive cells in the 3D
organotypic model involving Arr-HSC cells by comparison with
Ctrl-HSC cells. Bcl signaling is affected by arresten in both
endothelial cells and, according to our current data, also in
carcinoma cells (Figure 5G–H and [18,19]); the expression of anti-
apoptotic Bcl-xL decreased in both cell types, but the amount of
pro-apoptotic Bax increased only in the Arr-HSC carcinoma cells.
Nevertheless, the net result in both cell types is a shift in the
balance of pro-apoptotic and anti-apoptotic stimuli in a direction
that favors apoptosis. In subcutaneous xenografts, however, only
few apoptotic cells were detected that were located mainly in
dyskeratotic areas. It seems to depend on the composition of the
surroundings whether the cells are responding to arresten by
reduced proliferation or increased apoptosis. However, in the end
the net result in both experimental set-ups is the same: smaller
xenografts in mice and thin top cell layer in 3D model. Taken
together, we consider likely that besides inducing apoptosis
arresten can also reduce the proliferation of HSC-3 cells, which
leads to reduced tumor growth via two routes.
Another clear effect that arresten overexpression had on
carcinoma cells was the change in their morphology. Both the
Arr-HSC and Arr-MDA cells grew in aggregates that were tightly
attached to each other, whereas the control cells displayed a more
spindle-shaped and mesenchymal-like morphology (Figure 4A,
Figure S2E). This was concomitant with up-regulation of E-
cadherin expression and its localization in cell-cell contacts in the
Arr-HSC cells. Histopathologic evaluation of subcutaneous
xenografts suggested that arresten overexpression affected tumor
differentiation in vivo, Arr-HSC tumors containing more often
keratinized areas and keratin pearls than Ctrl-HSC tumors. The
clear membranous E-cadherin staining was localized around these
keratinized areas. The ECIS experiments and modeling
(Figure 6A, Figure S9) also supported our notion that HSC-3
cells form tighter cell-cell and cell-substrate contacts in the
presence of arresten. The loss or down-regulation of cell-cell
adhesion is crucial for the cells to metastasize, and it is considered
to be one of the key features of EMT [43]. EMT-like changes are
reversible, however, and thus the cells can restore their non-motile
Figure 4. Arresten promotes an epithelial morphology of HSC-
3 cells and increases the amount E-cadherin in cell-cell
contacts. A. Arresten overexpression induced a cobblestone-like
appearance in HSC-3 tongue squamous cell carcinoma cells (2006mag-
nification). B. Immunostaining of E-cadherin (red) in cultured Ctrl-HSC
and Arr-HSC cells (blue, DAPI). Scale bar 10 mm. C. 10 mg of total
protein from lysed cell extracts was analyzed by Western blotting with
E-cadherin antibody. b-actin was used as a loading control. D. The
relative band intensities were quantified (n = 3 Western analyses from
separate protein extractions; mean 6 SEM). E. mRNA expression of E-
cadherin in cultured Ctrl-HSC (N= 6, n = 12) and Arr-HSC (N= 3, n = 6)
cells (N = number of clones analyzed; n =number of samples analyzed).
The expression levels were normalized to that of the GAPDH
housekeeping gene and are presented relative to values obtained for
Ctrl-cells (mean 6 SEM) Students t-test, ***p,0.001, *p,0.05.
doi:10.1371/journal.pone.0051044.g004
Arresten Inhibits Carcinoma Cell Invasion
PLOS ONE | www.plosone.org 6 December 2012 | Volume 7 | Issue 12 | e51044
Arresten Inhibits Carcinoma Cell Invasion
PLOS ONE | www.plosone.org 7 December 2012 | Volume 7 | Issue 12 | e51044
epithelial characteristics in the MET process. Approximately a 2-
fold excess of E-cadherin in A431 human epidermoid carcinoma
cells has been shown inhibit their invasion [41] which is in line
with the degree of E-cadherin up-regulation induced by arresten in
our experiments (Table S1). Our data therefore suggest that
carcinoma cells undergo changes resembling MET in the presence
of arresten.
Arresten mediates its effects on endothelial cells through
integrin receptors. Arresten is known to bind to a1b1 integrin
and this ligation is shown to lead to the inhibition of focal adhesion
kinase (FAK)/c-Raf/MEK1/2/p38/ERK1 mitogen-activated
protein kinase pathway and suppression of endothelial cell
migration, proliferation, and tube formation [16–19,44]. Integrin
a1 is also required for the anti-survival effect of arresten in
endothelial cells [18]. Using ECIS measurements we showed here
that the high impedance of Arr-HSC cells was reduced upon
treatment with the function-blocking a1 integrin antibody. These
data suggest that a1b1 integrin mediates the promoting effect of
arresten on HSC-3 cell-cell contacts and cell spreading that are
disturbed upon antibody binding. Blocking of a2b1 integrin
receptor had a strong inhibitory effect on both the Arr-HSC and
the Ctrl-HSC cell attachment suggesting that this receptor
mediates interactions that do not involve arresten. Thus, the
upregulation of E-cadherin on cell-cell junctions and the
concomitant less invasive behavior may be linked to modulation
of integrin a1b1 signalling by arresten. The manipulation of b1
integrin and subsequent signaling pathways can lead to reversion
of the malignant phenotype [45–46]. The ECM proteoglycan
versican, known to interact and signal through b1-integrin [47],
was recently shown to induce MET in MDA-MB-231 cells [48]
further supporting the concept that alterations in the ECM can
regulate epithelial plasticity. We also consider it possible that the
excess of arresten disturbs the cell-matrix interactions in the
collagen I-based 3D organotypic model resulting in induction of
cell death.
ECM molecules, such as collagen I, for example, induce EMT
by an integrin and FAK-mediated regulation of cadherins, both by
disrupting E-cadherin adhesion complex and by upregulating N-
cadherin expression [39,27,49]. A correctly assembled collagen IV
network supports the differentiated epithelial cell phenotype, and
disruption of this network by administration of the a1(IV)NC1
domain has been shown to facilitate EMT in mouse proximal
tubular epithelial cells in vitro [50]. This observation differs from
the epithelial morphology-promoting effect of arresten on oral
carcinoma cells shown here, but these two phenomena represent
distinct types of transitions [22] and diverse cells may respond in
a different manner to stromal signals. Assadian et al. published
recently a study which shows that p53 can induce an anti-
angiogenic program whereby expression of a1(IV) chain is
upregulated, stabilized by prolyl-4-hydroxylase and efficiently
processed by MMPs to an arresten-containing peptide [20]. This
p53-dependent ECM remodeling was suggested to destabilize the
vascular collagen IV network and thereby prevent endothelial cell
adhesion and migration leading to reduced angiogenesis and
tumor growth in vivo and in vitro. Our observations on the
inhibition of tumor angiogenesis and growth by arresten are in
line with these observations, but our data suggest that arresten also
reduces proliferation, induces apoptosis and facilitates epithelial
plasticity in tumor cells. As tumor cells respond to many
biologically active molecules in biphasic manner [51–52], the
effects of arresten may also vary depending on its level. To date,
the systemic or local concentration of arresten is not known [20],
although a pilot study by Ramazani et al. suggests that the normal
circulatory level of collagen IV is around 100 ng/ml in healthy
humans giving us some cues on the level or arresten [53].
We show here for the first time that arresten directly modulates
the behavior of carcinoma cells, and propose that this occurs at
least partially via binding to integrin a1b1. Oral squamous cell
carcinoma and breast carcinoma cells overexpressing arresten
changed to a more epithelial-like phenotype, possibly reflecting
Figure 5. Arresten increases apoptosis of HSC-3 carcinoma cells in the organotypic model. A. Organotypic sections were stained for the
proliferation marker Ki-67 (brown). B. Proliferation was defined as a percentage of Ki-67-positive cells among the total number of carcinoma cells per
microscopic field (2006magnification; n = total number of fields analyzed, 3–5 fields per organotypic section). C–F. Apoptotic cells were detected by
TUNEL assay (green) and caspase-3 staining (red). Apoptotic cell death was quantified in terms of TUNEL (D) and caspase-3-positive (F) cells as
a percentage of total number of carcinoma cells per microscopic field (2006magnification; n = total number of fields analyzed, 3–5 fields per
organotypic section). Mann-Whitney U-test, ***p,0.001, *p,0.05. G. 20 mg of total protein of lysed cell extracts was separated by SDS-PAGE and
immunoblotted with antibodies against signaling molecules of the Bcl-family apoptosis pathway, anti-apoptotic Bcl-xL and pro-apoptotic Bax. b-actin
was used as a loading control. H. The relative band intensities were quantified (n = 3 Western analyses from separate protein extractions; mean 6
SEM). Students t-test, *p,0.05.
doi:10.1371/journal.pone.0051044.g005
Figure 6. Arr-HSC cell spreading is impaired in the presence of a function-blocking antibody to a1 integrin. A. The impedance,
reflecting cell adhesion and spreading, was measured for Ctrl-HSC and Arr-HSC cells using electric cell-substrate impedance sensing (ECIS) (mean of
duplicate wells of representative ECIS plates). The Arr-HSC cells showed markedly higher impedance at a low frequency than the control cells. B.
Treatment of Arr-HSC cells with a specific function-blocking a1 antibody reduced the impedance when compared to the untreated Arr-HSC cells.
Treatment of Arr-HSC cells with integrin a2 antibody almost completely abolished the cell spreading. C. Ctrl-HSC cells showed reduced spreading in
the presence of integrin a2 antibody while a1 antibody had no effect on impedance.
doi:10.1371/journal.pone.0051044.g006
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ongoing MET-like events, and subsequently became less motile
and more apoptotic. However, the MET-like events may not
always be beneficial for survival, as MET has also been reported
during the establishment of metastases. Furthermore, some ECM
molecules have been found to contribute to the formation of
premetastatic niches [30,54]. In summary, since arresten is a potent
inhibitor of angiogenesis, and also exerts strong anti-invasive
effects on carcinoma cells, it could be considered a candidate for
drug development efforts. However, the MET-inducing property
of arresten and its role in primary tumors and metastases should be
first characterized in detail.
Materials and Methods
Ethics Statement
The tumor experimentation in mice was approved by the ethics
committees of the State Provincial Offices of Oulu and Southern
Finland (permit numbers OLH-2006-02521/Ym-23, OLH-2006-
01987/Ym-23, ESLH-2008-03956/Ym-23, ESLH-2008-09631/
Ym-23). The carcinoma cell injections were performed under
isofluran anesthesia, and every effort was made to minimize
suffering, e.g. by using Rimadyl for pain relief after injections. A
tumor diameter of more than 10 mm was the criterion for
euthanasia.
Cell Culture
The culturing of the HSC-3 human tongue squamous
carcinoma cells (JCRB) and primary human fibroblasts obtained
from biopsies of healthy gingiva [55] is described in the
supplemental methods (Text S1).
Plasmid Constructs Transfection and Selection of HSC-3
and MDA-MB-435 Cells Expressing Arresten
The cDNA coding for human arresten construct [18] (a kind gift
from Raghu Kalluri, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA) was cloned into the
pcDNA3.1 expression vector (Invitrogen). HSC-3 and MDA-MB-
435 cells were transfected with these plasmids, or with an empty
pcDNA3.1 vector. The transfected cells were selected with
Geneticin G418 antibiotic (Invitrogen) to obtain stable populations
of cells expressing human arresten. The clones used in the
experiments were named Ctrl-HSC, Arr-HSC(1), Arr-HSC(2),
Ctrl-MDA, Arr-MDA(1) and Arr-MDA(2). Detailed cloning and
transfection protocols are presented in supplemental methods
(Text S1).
Purification of Recombinant Arresten
Recombinant arresten was purified from culture media of
HEK- 293 cells that had been stably transfected with the arresten
plasmid described above. Recombinant arresten was purified from
the conditioned media using an ANTI-FLAGR M2 affinity column
(Sigma-Aldrich). Details are described in supplemental methods
(Text S1).
Transwell Migration Assays
The Transwell migratory capacities of the Ctrl-HSC and Arr-
HSC cell lines were studied by plating cells into 6.5-mm diameter
and 8.0-mm pore size membrane Transwell inserts (Costar). The
inserts were equilibrated in serum-containing medium for 2 h, the
cells were trypsinized and 30 000 cells in 100 ml of serum-
containing medium were plated into each well and 600 ml of
serum-containing medium was added to the lower chamber.
Alternatively, native HSC-3 cells were suspended into media with
purified recombinant arresten (0, 5, or 20 mg/ml), and same
amount was also added to the lower chambers. The cells were
allowed to migrate overnight, fixed in 10% TCA, washed and
stained with 0.1% crystal violet. The cells that had migrated to the
underside of the membrane were counted under a Leica DMRB
microscope (Leica Microsystems). In the co-culture migration
assays the inserts were equilibrated for 2 h with media collected
from Arr-HSC cells for 24 h. The Ctrl-HSC cells were then
suspended in the co-culture medium and plated on the Transwell
wells as described above.
Scratch Wound Healing Assay
Cells were seeded on chamber slides (Lab-Tek, Nunc) and
grown to confluence. A cell-free wound was generated by scraping
the confluent monolayer with a pipette tip (500 ml, ART,
Molecular Bioproducts). The cells were fixed, stained with crystal
violet, examined under a microscope (Leica Microsystems) and
photographed at 0, 16 and 48 h time points. The width of the
wound in each high power field (506) was quantified (2–3 wounds
were generated per chamber, at least three pictures were taken of
each wound and at least three measurements were performed on
each picture).
Tumor Xenografts in Nude Mice
One million Ctrl-HSC and Arr-HSC cells in 200 ml of serum-
free media were subcutaneously injected into both flanks of 11-
week-old Balb/c nu/nu nude female mice (Harlan). Each group
contained ten mice. Tumor growth was measured at days 6, 13
and 16, and tumor volumes were calculated with the formula
length6width260.52. At day 16, the mice were sacrificed and the
tumors were collected for histology.
Histology and Immunohistochemistry of the Xenografts
The tumors were fixed in 4% neutral buffered formalin
overnight. 5-mm sections were deparaffinized and stained with
Mayers hematoxylin-eosin. A pathologist evaluated the degree of
invasion of each hematoxylin-eosin-stained tumor in a blinded
fashion. To detect the numbers of proliferating cells in HSC-3
xenografts, tumor sections were stained with Ki-67-antibody
(Dako) as described previously [56]. Quantification was performed
by counting the number of Ki-67 positive cells relative to non-
stained cells in each high power field (4006magnification). Blood
vessels were stained with CD31 (BD Biosciences PharMingen),
according to a previously published protocol [57], and their
numbers were counted.
Immunofluorescent Staining of Cells
Cells grown on coverglasses were fixed for 10 min in 4%
paraformaldehyde–PBS, blocked and permeabilized for 20 min
with 0.5% BSA/0.2% gelatine/0.1% Triton X-100 in PBS and
incubated with primary anti-E-cadherin (Cell Signaling Technol-
ogy) and anti-vimentin Ab-2 (NeoMarkers) antibodies in 0.5%
BSA/0.2% gelatine–PBS overnight at 4uC. The secondary Cy2
and Cy3-conjugated antibodies (Jackson ImmunoResearch Labo-
ratories) were applied for 45 min at room temperature. 49,69-
diamino-2-phenylindole hydrochloride (DAPI) was added to
visualize the cell nuclei. Confocal images were captured using
a laser confocal microscope (Olympus IX81).
Organotypic Cultures
In the organotypic assays the carcinoma cells were allowed to
invade into a 3-D mixture of collagen and human gingival
fibroblasts. The collagen gels were prepared as previously
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described [56]. Briefly, 8 volumes of collagen type I (3.45 mg/ml;
BD Biosciences), 1 volume of 106DMEM (Sigma) and 1 volume
of FBS with gingival fibroblasts (76105 cells) were allowed to
polymerize at 37uC for 30 min. After polymerization, 76105
HSC-3 cells (Ctrl-HSC and Arr-HSC) were added to each gel.
The gels were lifted onto collagen-coated (BD Biosciences) nylon
discs (Prinsal Oy) resting on curved steel grids that were placed on
6-well plates. Medium was added to reach the undersurface of the
grid, generating an air-liquid interface. Quantification of invasion
was performed to identify carcinoma cells according to a previously
published protocol based on pancytokeratin immunostaining
(AE1/AE3 antibody, Dako) [56]. Briefly, the areas of immunos-
tained non-invading and invading cells were calculated, and the
average invasion depth per microscopic field (the distance of the
invaded cell clusters from the lower surface of the non-invasive cell
layer) was measured in each sample according to a previously
published protocol [56].
Histology and Immunohistochemistry of the Organotypic
Cultures
The organotypic discs were fixed in 4% neutral buffered
formalin overnight. 6-mm sections were deparaffinized and stained
with Mayers hematoxylin-eosin. For immunohistochemistry of
pancytokeratin AE1/AE3 antibody (Dako) the endogenous
peroxidase activity was blocked with 0.3% H2O2 in MeOH for
30 min. Antigen retrieval was performed with 0.4% pepsin in
0.01 M HCl at 37uC for 1 h or by microwaving (T/T Mega) the
sections in citrate buffer (REAL Target Retrieval Solution, pH 6;
Dako) or in Tris/EDTA (10 mM Tris, 1 mM EDTA, pH 9) for
20 min. The sections were blocked with normal serum (Vector
Laboratories) in 2% BSA/PBS for 30 min and incubated with
primary antibody at 37uC for 30 min and at 4uC overnight.
Biotinylated secondary antibody (Vector) was applied for 1 h and
StreptABComplex/HRP (Dako) in 0.5 M NaCl/PBS for 30 min.
E-cadherin (Cell Signaling Technology) was stained using the
REAL EnVision Detection System (Dako) according to the
manufacturers instructions; it was incubated at 4uC overnight,
after which the secondary antibody was applied for 30 min. The
presence of the antigen was visualized using DAB Peroxidase
Substrate (Vector) for 3 min and counterstained. In the negative
controls normal serum or IgG of the appropriate species (Dako)
was used instead of the primary antibody. Organotypic cultures
were stained with Ki-67 (Dako) to detect the numbers of
proliferating cells as described previously [56]. Quantification
was performed by counting the number of Ki-67 positive cells
relative to non-stained cells in each high power field (2006mag-
nification).
Apoptosis Assays
The terminal deoxynucleotidyl transferase-mediated dUTP nick
end-labelling (TUNEL) assay and caspase-3 immunostainings
were used to quantify the apotosis of cells overexpressing arresten
and control HSC-3 cells grown in organotypic cultures. In the
TUNEL assay the apoptotic cells were labeled according to the
instructions of the In Situ Cell Death Detection Kit (Roche). The
bright green apoptotic nuclei were viewed with a DMRB photo
microscope connected to a DFC-480 camera using QWin V3
software (Leica Microsystems). Quantification was performed by
counting the TUNEL positive green cells relative to the non-
stained cells in each high power field (2006). For the caspase-3
staining the antigen retrieval was done by boiling in 0.01 M
EDTA. The staining was done with Histomouse SP-KIT
(Invitrogen). The primary antibody (cleaved caspase-3 D175,
1:200 in 1% BSA in PBS, R&D Systems) was incubated overnight
at +4uC. The slides were incubated in secondary antibody for
30 min RT and the enzyme conjugate for 10 min. Subsequently,
the slides were incubated in substrate-chromophore mixture for
8 min RT, and embedded in Cole hematoxylene and mounted.
ECIS Assays
Electric cell-substrate impedance sensing (ECIS) (Applied
Biophysics Inc) was used to study cell adhesion. The cells were
trypsinized and 400 000 cells in 400 ml were seeded on an 8-well
ECIS plate to monitor cell spreading by means of impedance.
Before plating the cells were treated 10 mg/ml integrin a1 or a2
blocking antibodies (mouse anti-human clone FB12, Millipore or
goat anti-human N-19, Santa Cruz, respectively) or control IgG
(Dako) for 15 min on ice. A mathematical ECISTM model of the
impedance changes was used to refine the ECIS data and to
calculate cell morphological parameters (the barrier function of the
cell layer, Rb; the spacing between the cell and the substratum, a;
and the cell membrane capacitance, Cm [36–37].
Statistical Analysis
SPSS 16.0 software was used for the statistical calculations. The
results are presented as medians [25th percentile, 75th percentile]
in boxplots, where the whiskers represent data points lying within
1.5 interquartile ranges of the median. The qPCR data, scratch
wound healing results, quantification of Western blot band
intensities and tumor growth curves are presented as means +/
2 standard error of mean (SEM). The Mann-Whitney U-test or
Students t-test were used to determine statistical significance.
Supporting Information
Figure S1 Characterization of stable HSC-3 and MDA-
MB-435 cell clones overexpressing arresten by Western
blotting. The secretion of recombinant arresten in stably
transfected HSC-3 and MDA-MB-435 cells was verified by
Western blotting. The cell culture medium was concentrated by
acetone precipitation and the proteins were separated by SDS-
PAGE and immunoblotted with anti-Flag antibody. Representa-
tive immunoblots of HSC-3 vector control Ctrl-HSC(1) and the
HSC-3 arresten clones Arr-HSC(1) and Arr-HSC(2) (A), and
MDA-MB-435 vector control Ctrl-MDA(1) and theMDA-MB-435
arresten clones Arr-MDA(1) and Arr-MDA(2) (B).
(TIF)
Figure S2 Arresten inhibits migration of HSC-3 and
MDA-MB-435 cells, and induces morphological changes
in MDA-MB-435 cells in vitro. A.Wound closure in a scratch
wound healing assay was markedly slower in both Arr-HSC clones
than in the Ctrl-HSC cells. Scale bar 50 mm. B. MDA-MB-435
wounds did not close within 48 h, but both Arr-MDA clones
showed reduced migration relative to the Ctrl-MDA cells. Scale
bar 50 mm. C. Quantification of wound closure in the Ctrl-HSC
and Arr-HSC clones (n = 9 fields per clone at 0 h, n= 18 at 16 and
48 h). Mann-Whitney U-test, ***p,0.001. D. Quantification of
wound closure in the Ctrl-MDA and Arr-MDA clones (n = 26
fields per clone at 0, 16 and 48 h). Mann-Whitney U-test,
***p,0.001. E. Arresten overexpression induced a cobblestone-
like appearance in a representative clone of MDA-MB-435 breast
carcinoma cells (1006magnification).
(TIF)
Figure S3 Overexpression of arresten reduces the
viability of HSC-3 cells in 2D culture. A. Proliferative cells
were detected by BrdU labeling. 5000 Ctrl-HSC and Arr-HSC
cells were allowed to attach and the cell proliferation was
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measured after 24 h using the colorimetric cell proliferation
ELISA BrdU assay at 450 nm (n= 10 wells). B. Viable cells were
detected by MTT assay. 5000 Ctrl-HSC and Arr-HSC cells were
allowed to grow on 96-well plates for 68 hours before exposure to
MTT reagent. Formed crystals inside the viable cells were
dissolved in DMSO and the absorbance was measured at
540 nm (n= 18 wells). Mann-Whitney U-test, ***p,0.001.
(TIF)
Figure S4 Conditioned Arr-HSC culture medium inhi-
bits HSC-3 cell migration in co-culture experiments.
Conditioned media from Ctrl-HSC (CtrlCM) and Arr-HSC
(ArrCM) clones were collected at 24 h and administered to Ctrl-
HSC cells. A. Cell migration was assayed with a Transwell assay in
which 30 000 cells were allowed to migrate through Transwell
inserts and the number doing so was counted under a microscope
with 506magnification. Mann-Whitney U-test, ***p,0.001,
(n = total number of fields analyzed, 3–5 fields per Transwell
insert). B. Recombinant arresten is stable in co-culture at 37uC
and in storage at 4uC. The CM was collected from Arr-HSC cells
after 48 h culture period. ArrCM was administered to Ctrl-HSC
cells and medium samples were collected after 24 h and 72 h
incubations at 37uC. A sample of ArrCM stored for72 h at 4uC
was also included in the analysis. The CM proteins were
concentrated with acetone precipitation and analyzed by Western
blotting with an anti-Flag antibody.
(TIF)
Figure S5 Arresten inhibits cell invasion in vitro. 30 000
Arr-HSC and Ctrl-HSC cells were allowed to invade through the
Matrigel-coated Transwell inserts for 22 hours. The invaded cells
were stained with hematoxylin and counted under a microscope
with 206magnification. Mann-Whitney U-test, *p,0.05, (n = total
number of fields analyzed, 3–5 fields per Transwell insert).
(TIF)
Figure S6 Arresten alters the tissue architecture of
HSC-3 xenografts. One million Ctrl-HSC and Arr-HSC cells
were injected subcutaneously into the flanks of nude mice
(n = 10 per group) and tumor growth was monitored over 16
days. Representative hematoxylin-eosin and E-cadherin stainings
of HSC-3 xenografts. A–B. Ctrl-HSC xenografts show an
appearance of poorly differentiated squamous cell carcinomas
(A). Some tumors contain also keratinized areas (dotted line) in
central tumor area (B). C–D. Arr-HSC xenografts resemble
moderately or well differentiated squamous cell carcinomas, and
relative to the Ctrl-HSC tumors, show more pronounced
keratinized areas (dotted line) and keratin pearls (arrowhead),
sometimes surrounded by a thin layer of poorly differentiated cells
(D). Scale bar 500 mm (A, B, D) and 100 mm (C). E–H.
Immonostaining for E-cadherin (brown) showed either diffuse
cytoplasmic signals in the poorly differentiated tumor areas
(arrow), or membranous staining (open arrow) within the
keratinized areas in all xenografts. Scale bar 100 mm. T= tumor;
K= keratinized area; N=necrosis.
(TIF)
Figure S7 No differences in vimentin staining between
Arr-HSC and Ctrl-HSC cells. Immunostaining of vimentin
(green) in cultured Ctrl-HSC and Arr-HSC cells (blue, DAPI).
Scale bar 100 mm.
(TIF)
Figure S8 Tunel-positive cells were detected in kerati-
nized or necrotic areas in HSC-3 xenografts. Apoptotic
cells were detected by TUNEL assay (green) in HSC-3 xenografts
(blue, DAPI). Scale bar 100 mm.
(TIF)
Figure S9 Cell-cell and cell-substrate interactions, and
cell membrane capacitance show changes between Arr-
HSC and Ctrl-HSC cells. A. The impedance, reflecting cell
adhesion and spreading, was measured for Ctrl-HSC cells treated
with ArrCM or CtrlCM using electric cell-substrate impedance
sensing (ECIS) (mean of duplicate wells of representative ECIS
plates). HSC-3 cells treated with ArrCM showed higher
impedance than those treated with CtrlCM. B. Ctrl-HSC cells
showed reduced spreading in the presence of integrin a2 antibody
while control IgG and a1 antibody had no effect on impedance.
C–E. A mathematical ECISTM model of the impedance changes
was used to refine the ECIS data and to calculate cell
morphological parameters. The barrier function of the cell layer,
Rb (C), and the spacing between the cell and the substratum,
a (D), were significantly higher in Arr-HSC than in Ctrl-HSC
cells. Mann-Whitney U-test, **p,0.01, *p,0.05. E. The cell
membrane capacitance, Cm, was significantly decreased in Arr-
HSC cells in comparison with Ctrl-HSC cells. Mann-Whitney U-
test, **p,0.01. (n = number of ECIS wells).
(TIF)
Table S1 Relative mRNA expression of arresten and E-
cadherin in the HSC-3 and MDA-MB-435 clones.
(DOC)
Text S1 Supplemental methods. Cell culture, cloning of
arresten into pcDNA3.1 eukaryotic expression vector, transfection
and selection of HSC-3 and MDA-MB-435 cells expressing
arresten, purification of recombinant arresten, quantitative real-
time RT-PCR (qPCR), cell proliferation assay, MTT viability
assay, Transwell invasion assay, E-cadherin staining and apoptosis
assay for HSC-3 xenografts and Western blotting.
(DOC)
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